In this study, we retrospectively analyzed 42 patients who received tisa-cel at our institution to identify pre-infusion factors for predicting early (within 3 months) disease progression or relapse. The median follow-up period was 8.2 (range, 0.2-36.5) months, and 16 patients (38.1%) had early disease progression/relapse after tisa-cel infusion. Primary refractory cases before leukapheresis and a high lactate dehydrogenase level (>1.5×upper limit of normal) and extranodal involvement ≥2 before lymphodepleting chemotherapy were the significant factors predicting early disease progression or relapse after tisa-cel infusion. In particular, 9 out of 10 (90%) patients with de novo DLBCL and primary refractory course developed disease progression within 4 months after tisa-cel infusion, suggesting the importance of considering new treatment strategies in these patients.